Status:
COMPLETED
A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Post-Operative Nausea and Vomiting
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A new intravenous medication is being tested for the prevention of the nausea and vomiting that occurs after surgery. This new medication is being compared to another intravenous medication that is al...
Eligibility Criteria
Inclusion
- Open abdominal surgery requiring 24 hour hospital stay
- General anesthesia
- Post-operative opioids
- ASA status of I-III
Exclusion
- Patient exhibits evidence of any clinically significant respiratory, metabolic, hepatic, renal dysfunction, or cardiovascular condition or congestive heart failure (CHF)
- Morbid obesity
- Patient is mentally incapacitated or has a significant emotional or psychiatric disorder
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT00231777
Start Date
July 1 2005
End Date
November 1 2005
Last Update
August 19 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.